$KRTL KRTL Biotech Inc. Introduces Expanded Pharma
Post# of 22
(Total Views: 59)
Posted On: 09/25/2025 9:30:28 AM
$KRTL KRTL Biotech Inc. Introduces Expanded Pharmaceutical Portfolio Following Strategic Acquisition
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=493619
KRTL Holding Group, Inc. (OTC: KRTL) (“KRTL Holding” or the “Company”) today announced that its majority owned subsidiary, KRTL Biotech, Inc. (“KRTL Biotech”), now holds exclusive rights to a robust pharmaceutical product catalog following the recently completed merger of Industria Químico Farmacéutica SIGMA Corp SRL. agreement.
This integration marks a significant expansion of KRTL Biotech’s capabilities across the pharmaceutical value chain, including formulation, packaging, and distribution of essential medications spanning more than a dozen therapeutic areas.
“This catalog reflects decades of medical advancement and our dedication to delivering quality medicines throughout Bolivia and beyond,” said Patricia Wilstermann, CEO of SIGMA. “We are honored to see our work reach new markets through this partnership and are confident in the value it brings to both our communities and KRTL Biotech’s global vision.”
“With this merger, KRTL Biotech now has access to a comprehensive pharmaceutical portfolio produced in accordance with national GMP standards and backed by decades of successful market presence in Latin America,” said Dan Bishop, CEO of KRTL Biotech Inc. “These assets position KRTL Biotech to enter new markets and align with future U.S. regulatory initiatives.”
Product Portfolio Overview
The acquired catalog includes over 150 registered pharmaceutical products, offering a strategically balanced mix of high-demand, essential therapies and specialized health solutions. This portfolio not only reflects regional healthcare priorities but also introduces a foundation of GMP-certified products that can be adapted for broader international commercialization. It spans the following categories:
Antibiotics and Antivirals
Digestive and Gastrointestinal Treatments
Cardiological and Urological Therapies
Analgesics and Anti-Inflammatories
Dermatological and Ophthalmological Formulations
Cognitive Enhancers and Vitamin Supplements
Biosecurity Products and Dental Health Solutions
Nutraceuticals and Functional Health Products
This broad range of products—including nutraceuticals, antibiotics, cardiovascular treatments, and pediatric formulations—reflects KRTL Biotech’s deep commitment to addressing both immediate public health needs and emerging healthcare trends across diverse markets. These offerings are strategically aligned with growing global demand for preventive care, accessible treatments, and tailored therapies across multiple age groups and conditions. Some of these categories are also the focus of government-supported initiatives in Bolivia aimed at improving long-term wellness and preventive care. KRTL Biotech will continue to release more detailed announcements highlighting specific product areas, manufacturing initiatives, and regional strategies in both Latin America and the United States.
Dosage forms include tablets, capsules, syrups, injectables, emulsions, and topical agents, manufactured for both pediatric and adult populations.
Strategic Importance of the Product Catalog
This extensive catalog introduces a diverse range of high-demand pharmaceutical products, many of which align with current public health needs and market gaps in the United States. The company is now positioned to evaluate strategic import opportunities and supply select medications across therapeutic areas where accessibility, affordability, and reliability are in high demand.
Flagship products from the catalog include those already proven in Latin American markets and others prioritized for near-term regulatory evaluation in the United States. These selections reflect both commercial readiness and strategic alignment with KRTL Biotech's expansion objectives:
Broad-spectrum antibiotics and antivirals
Pediatric formulations in palatable liquid and chewable forms
Cardiovascular treatments with standardized dosages
High-demand OTC medications such as analgesics and antihistamines
Multivitamin supplements tailored for prenatal and geriatric populations
These products are manufactured under stringent GMP conditions, providing a compliant foundation for future regulatory alignment. KRTL Biotech is committed to bridging global pharmaceutical quality with U.S. healthcare needs through responsible sourcing, scalable logistics, and forward-looking distribution strategies.
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=493619
KRTL Holding Group, Inc. (OTC: KRTL) (“KRTL Holding” or the “Company”) today announced that its majority owned subsidiary, KRTL Biotech, Inc. (“KRTL Biotech”), now holds exclusive rights to a robust pharmaceutical product catalog following the recently completed merger of Industria Químico Farmacéutica SIGMA Corp SRL. agreement.
This integration marks a significant expansion of KRTL Biotech’s capabilities across the pharmaceutical value chain, including formulation, packaging, and distribution of essential medications spanning more than a dozen therapeutic areas.
“This catalog reflects decades of medical advancement and our dedication to delivering quality medicines throughout Bolivia and beyond,” said Patricia Wilstermann, CEO of SIGMA. “We are honored to see our work reach new markets through this partnership and are confident in the value it brings to both our communities and KRTL Biotech’s global vision.”
“With this merger, KRTL Biotech now has access to a comprehensive pharmaceutical portfolio produced in accordance with national GMP standards and backed by decades of successful market presence in Latin America,” said Dan Bishop, CEO of KRTL Biotech Inc. “These assets position KRTL Biotech to enter new markets and align with future U.S. regulatory initiatives.”
Product Portfolio Overview
The acquired catalog includes over 150 registered pharmaceutical products, offering a strategically balanced mix of high-demand, essential therapies and specialized health solutions. This portfolio not only reflects regional healthcare priorities but also introduces a foundation of GMP-certified products that can be adapted for broader international commercialization. It spans the following categories:
Antibiotics and Antivirals
Digestive and Gastrointestinal Treatments
Cardiological and Urological Therapies
Analgesics and Anti-Inflammatories
Dermatological and Ophthalmological Formulations
Cognitive Enhancers and Vitamin Supplements
Biosecurity Products and Dental Health Solutions
Nutraceuticals and Functional Health Products
This broad range of products—including nutraceuticals, antibiotics, cardiovascular treatments, and pediatric formulations—reflects KRTL Biotech’s deep commitment to addressing both immediate public health needs and emerging healthcare trends across diverse markets. These offerings are strategically aligned with growing global demand for preventive care, accessible treatments, and tailored therapies across multiple age groups and conditions. Some of these categories are also the focus of government-supported initiatives in Bolivia aimed at improving long-term wellness and preventive care. KRTL Biotech will continue to release more detailed announcements highlighting specific product areas, manufacturing initiatives, and regional strategies in both Latin America and the United States.
Dosage forms include tablets, capsules, syrups, injectables, emulsions, and topical agents, manufactured for both pediatric and adult populations.
Strategic Importance of the Product Catalog
This extensive catalog introduces a diverse range of high-demand pharmaceutical products, many of which align with current public health needs and market gaps in the United States. The company is now positioned to evaluate strategic import opportunities and supply select medications across therapeutic areas where accessibility, affordability, and reliability are in high demand.
Flagship products from the catalog include those already proven in Latin American markets and others prioritized for near-term regulatory evaluation in the United States. These selections reflect both commercial readiness and strategic alignment with KRTL Biotech's expansion objectives:
Broad-spectrum antibiotics and antivirals
Pediatric formulations in palatable liquid and chewable forms
Cardiovascular treatments with standardized dosages
High-demand OTC medications such as analgesics and antihistamines
Multivitamin supplements tailored for prenatal and geriatric populations
These products are manufactured under stringent GMP conditions, providing a compliant foundation for future regulatory alignment. KRTL Biotech is committed to bridging global pharmaceutical quality with U.S. healthcare needs through responsible sourcing, scalable logistics, and forward-looking distribution strategies.
(0)
(0)